Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Primary: To determine the pathological remission following the chemotherapy combination
docetaxel and doxorubicin in large breast cancer
Secondary:
- Clinical response rate
- To investigate the safety of docetaxel doxorubicin combination in the treatment for
neoadjuvant chemotherapy of breast cancer
- Type of surgery (radical/conservative)